On Thursday, one of the biggest drug company, Sanofi-Aventis posted an 8.6% increase in fourth-quarter net revenue, elevated by its diabetes drug Lantus, achievement and an increase from sales of A H1N1 flu vaccines.

It has been reported that net revenue for the three months ended on March 31 was €1.71 billion ($2.26 billion) compared to €1.58 billion in the previous year.

According to a Dow Jones Newswires survey of 9 analysts, Sanofi's profit mounted 3.9%, to €7.39 billion.

Rapid sales development from Lantus aided to counterbalance a plunge in profits from generic opposition to its cancer drug Eloxatin.

According Sanofi , it expects to record increase of "business" earnings per share at stable rates of between 2% and 5%in 2010, apart from the effect of possible generic opposition to its Lovenox.

Last year, Sanofi Chief Executive, Chris Viehbacher has constructed the firm’s achievement policy around vaccines, generics and over-the-counter portfolios.

About €6.6 billion-worth of acquisitions was made by the firm in 2009.

Shares of Sanofi have mounted almost 20% in the past one year, at a comparable rate to the Paris CAC-40 index, up 22% over the similar time.